Radiolocalization of human prostate tumor in a mouse subrenal capsule model by monoclonal antibody turp‐27

Abstract

The subrenal capsule assay was used to determine if 125I-labeled anti-prostate monoclonal antibody TURP-27 could target human prostate tumor fragments implanted under the renal capsule of normal immunocompetent C57 BL/6 mice. Maximal binding and optimal tumor to non-tumor tissue ratios occurred within 24-48 hours postadministration of 125I-TURP-27. No significant localization was observed in mice bearing TURP-27 antigen-negative human colon tumor tissue implants or with an isotype-matched control monoclonal antibody. These preclinical data suggest that TURP-27 may have clinical application for imaging metastatic prostate tumors and further application in immunoconjugate and/or radiotherapy of prostate cancer.

A novel prostate carcinoma‐associated glycoprotein complex (PAC) recognized by monoclonal antibody turp‐27

“…This cross-reactivity may present a potential pitfall for clinical use of this antigenantibody system; however, several other MAbs with similar cross-reactivity have been successfully used in treatment or imaging regimens with only minor side-effects or none at all (Garin-Chesa et al, 1989;Houghton et al, 1985;Cheung et al, 1987;Pate1 et al, 1989). Such results are encouraging and suggest that MAb TURP-27 may yet find clinical utility for Recently we reported that 1251-labelled MAb TURP-27 could be used to specifically localize prostate explants placed under the murine subrenal capsule (Wright et al, 1990). This model system does not adequately evaluate the pharmacokinetics and dosimetry of injected immunoconjugates.…”

“…Such results are encouraging and suggest that MAb TURP-27 may yet find clinical utility for expressed by the PC-82 prostate carcinoma heterotransplant line (which h s o expresses PAP and PSA), is significant and evaluate the pre-clinical Of TURP-27 alone Or in conjunction with these other well-characterized prostate markers . Recently we reported that 1251-labelled MAb TURP-27 could be used to specifically localize prostate explants placed under the murine subrenal capsule (Wright et al, 1990). This model system does not adequately evaluate the pharmacokinetics and dosimetry of injected immunoconjugates.…”

Immunohistochemical evaluation of the expression of prostate tumor‐association markers in the nude mouse human prostate carcinoma heterotransplant lines PC‐82, PC‐EW, and PC‐EG

“…Unfortunately this tumor-associated antigen is not expressed by cultured prostate carcinoma cell lines PC3, DU145, and LNCaP or any of over 40 non-prostate malignant cell lines tested [ 141 (Wright et al, unpublished), The high expression (90% or greater) of this TAA by the PC-82 and PC-EW lines suggests that these transplant lines may be excellent models in which to develop radioimmunologic imaging strategies and for determining the potential effectiveness of TURP-27 antibody-conjugates for prostate carcinoma therapy. We recently reported that '251-labeled TURP-27 specifically targeted human prostate carcinoma implanted under the renal capsule of mice [22]. Although the mouse subrenal capsule model demonstrated the potential use of isotope-conjugated TURP-27 for targeting prostate carcinomas, the model is short term (3 days), such that pharmacokinetics and dosimetry determinations are almost impossible to perform.…”

Radioimmunoscintigraphy with a novel monoclonal antiprostate antibody (E4)

“…7,8 Many attempts have been made to produce MoAb reactive with prostate tissue. [9][10][11] The E4 MoAb used in the present study Localization Experiments was generated and tested in vitro by Essand.…”